Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$57.52 - $132.26
Previous CloseN/A
Volume488.69K
Average Volume (3M)4.80M
Market Cap
$32.00B
Enterprise Value$27.71B
Total Cash (Recent Filing)$904.90M
Total Debt (Recent Filing)$2.58B
Price to Earnings (P/E)60.3
Beta1.17
Next Earnings
Jul 24, 2025EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding392,107,500
10 Day Avg. Volume4,501,448
30 Day Avg. Volume4,798,028
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda31.14
Forecast
1Y Price Target
$97.69Price Target Upside14.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
New Product LaunchDXCM's announced FDA approval of the G7 15 Day sensor for people over the age of 18 in the US represents an incremental positive vs. expectations.
Sales PerformanceDexCom achieved a strong performance driven by U.S. sales and a record number of new patient additions.
Strategic PartnershipsA notable uptick in new starts from non-insulin dependent T2s occurred after an additional 5mn patients gained access, with more access expected following a new agreement with the third major PBM.
Bears Say
Cost ChallengesDXCM lowered its FY25 GM guidance to 62% due to higher inventory replenishment costs.
Gross Margin PressureDexCom faces a significant short-term headwind in gross margins due to increased costs from rebuilding inventory and freight expenses.
Supply Chain IssuesMargins came in below consensus due to supply chain issues and increased shipping costs.
---
Ownership Overview
0.46% Insiders
28.01% Mutual Funds
0.65% Other Institutional Investors
41.16% Public Companies and
Individual Investors
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $57.52 and its highest was $132.26 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $32.00B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 24, 2025 which is in 76 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on May 01, 2025. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.327 by -$0.007.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.45.
How many shares outstanding does Dexcom have?
Dexcom has 392,107,500 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.32 in its last earnings report, missing expectations of $0.327. Following the earnings report the stock price went up 16.169%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
---
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.69 (14.47% Upside)
$97.69 (14.47% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 73%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $432.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.11%
12-Months-Change
Fundamentals
Return on Equity
23.72%
Trailing 12-Months
Asset Growth
4.16%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
---
DXCM Company Deck
---
DXCM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, significant expansion in coverage for type 2 diabetes, and successful product innovations. However, challenges included a decline in gross margin due to supply chain issues and an FDA warning letter that required attention. Overall, while there are notable achievements, the presence of significant challenges suggests a balanced sentiment.Read More>---
DXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$97.69
▲(14.47% Upside)
Technical Analysis
---